Steven George Hughes - 22 Oct 2025 Form 4 Insider Report for Avidity Biosciences, Inc. (RNA)

Role
Chief Medical Officer
Signature
/s/ John B. Moriarty, Jr., J.D., Attorney-in-Fact
Issuer symbol
RNA
Transactions as of
22 Oct 2025
Net transactions value
-$82,571
Form type
4
Filing time
24 Oct 2025, 16:56:40 UTC
Previous filing
23 Sep 2025
Next filing
09 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Hughes Steven George Chief Medical Officer C/O AVIDITY BIOSCIENCES, INC., 3020 CALLAN RD., SAN DIEGO /s/ John B. Moriarty, Jr., J.D., Attorney-in-Fact 24 Oct 2025 0001747528

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RNA Common Stock Options Exercise $22,443 +2,209 +5.7% $10.16 41,076 22 Oct 2025 Direct F1
transaction RNA Common Stock Sale $105,015 -2,209 -5.4% $47.54 38,867 22 Oct 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RNA Stock Option (Right to Buy) Options Exercise $0 -2,209 -3.1% $0.000000 68,458 22 Oct 2025 Common Stock 2,209 $10.16 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024.
F2 This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $46.83 to $49.30. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 This option was granted on January 20, 2024 and vests in equal installments of 2,208 shares on each monthly anniversary of such grant date, until it is fully vested and exercisable on January 20, 2028.